What is Shift Bioscience?
Shift Bioscience is at the forefront of applying generative artificial intelligence to understand and manipulate the aging process. The company is developing a sophisticated cell simulation platform that integrates its proprietary biological aging clock with advanced AI models. This platform aims to accurately predict gene sets capable of safely rejuvenating specific cell types, paving the way for novel therapeutic interventions. Led by CEO Dr. Daniel Ives, Shift Bioscience's innovative technology positions it as a key player in the rapidly evolving field of longevity and regenerative medicine.
How much funding has Shift Bioscience raised?
Shift Bioscience has raised a total of $34M across 2 funding rounds:
Angel/Seed
$16M
Angel/Seed
$18M
Angel/Seed (2024): $16M with participation from Kindred Capital, BGF, and F-Prime Capital
Angel/Seed (2024): $18M led by Kindred Capital, F-Prime Capital, and BGF
Key Investors in Shift Bioscience
Kindred Capital
Kindred Capital is a FinTech company focused on providing innovative financial solutions and systems to enhance business operations, offering services like salary advance loans and working capital access.
BGF
BGF is the most active investor in small and mid-sized businesses in the UK, supporting companies across various stages of growth and sectors.
F-Prime Capital
F-Prime Capital invests in healthcare and technology companies, with a team of investors, engineers, doctors, and scientists dedicated to advancing these sectors.
What's next for Shift Bioscience?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Shift Bioscience. This capital infusion is expected to accelerate the development and validation of its AI-driven cell simulation platform, potentially enabling the company to move towards clinical trials and broader market application. The backing from prominent investors suggests strong confidence in Shift Bioscience's technology and its potential to disrupt the biotech landscape, particularly in age-related diseases and cellular repair.
See full Shift Bioscience company page
